CD28 and lymphoma: Although T cells expressing CARs with either a 4-1BB or CD28 costimulatory domain have demonstrated similar antitumor activity, particularly against lymphomas [7, 10, 167, 168], T cells expressing CD28-costimulated CARs display higher cytokine production but lower persistence [111, 169–171].